--- title: 'Associate Director, HEOR & Market Access, EU West at BridgeBio Pharma' canonical: 'https://feeny.ai/job/associate-director-heor-market-access-eu-west-bridgebio-pharma-france-6k1tdatpyfa7' type: 'job' last_seen: '2026-10-14' --- # Associate Director, HEOR & Market Access, EU West at BridgeBio Pharma - **Company:** BridgeBio Pharma - **Location:** France - **Work type:** remote - **Posted:** 2026-10-14 - **Last confirmed live:** 2026-10-14 - **Apply:** https://job-boards.greenhouse.io/bridgebio/jobs/5264696007 ## Job description Mavericks Wanted When was the last time you achieved the impossible? If that thought feels overwhelming, you might want to pause here, but if it sparks excitement...read on In 2015, we pioneered a “moneyball for biotech” approach, pooling projects and promising early-stage research from academia together under one financial umbrella to reduce risk and unleash innovation. This model allows science and small teams of experts to lead the way. We build bridges to groundbreaking advancements in rare disease, and develop life-changing medicines for patients with unmet needs as fast as humanly possible. Together we define white space, push boundaries, and empower people to solve problems. If you're someone who defies convention, join us and work alongside some of the most respected minds in the industry. Together, we'll ask "why not?" and help reengineer the future of biopharma. At BridgeBio, we value curiosity and experimentation—including the ethical & thoughtful use of AI to improve clarity, speed, and quality of work. ## What You’ll Do You will report to the Senior Director, Head of Market Access, EU West Region and work closely with Medical affairs, Market Access, Commercial locally and globally, to support BridgeBio’s mission of delivering transformative medicines to patients with genetic rare diseases. You will own the value demonstration strategy for our products across the region, and translate it into effective patient access: design each product's evidence generation plan, drive it through to delivery, and align it with pricing and access strategy, starting in France, then extending to the other countries of the EU West region Your main responsibilities include: Evidence generation - Design and lead natural history studies, cohorts, registries, and analyses of medico-administrative databases (SNDS, BNDMR/ BaMaRa, rare disease network registries) - Lead indirect comparisons in the context of single-arm trials and very small patient populations - Develop health economic models (cost-effectiveness, budget impact) for France, then for other markets in the region - Design real-world data collection frameworks (PUT-RD / data collection protocols) that can be reused for reassessment and in other countries - Define the scientific publication and communication plan Study management - Draft specifications, run tenders, and select vendors - Convene and lead external scientific advisory committees - Secure all required approvals (health data access, ethics committees, regulatory compliance) - Manage the administrative, contractual, and budgetary aspects of studies - Review and validate all deliverables (protocols, analysis plans, study reports, publications) Value communication and internal expertise - Translate study results into actionable clinical and economic arguments - Drive scientific dissemination (congresses, publications) - Serve as the internal reference point on epidemiology, health economics, and health data matters - Build and maintain a network of research agencies, academics, and institutions Value and access strategy - Define and own the value demonstration strategy for each product across the region - Build economic value propositions and value dossiers and ensure their local adaptation - Contribute to pricing strategy and preparation for CEPS negotiations (e.g., positive externalities, budget impact) - Coordinate and build the economic modelling and CEESP dossier (early scientific advice, modelling, CEESP submission, technical exchange, etc.) - Contribute the health-economic and RWE content of early access dossiers and submissions to the Transparency Committee, in coordination with the Market Access Director, with progressively increasing ownership of Benelux dossiers - Anticipate assessors' objections and build responses ahead of submission French rare disease ecosystem - Build working relationships with rare disease networks, reference and competence centres, patient associations, and learned societies - Negotiate collaborations with existing registries and cohorts - Contribute to documenting the patient journey and disease burden Function leadership and development - Own and arbitrate the region's HEOR and RWE budget - Structure the function (methods, quality standards, vendor panel, review processes) - Recruit and manage future team members - Represent the region to global HEOR and Market Access teams The above list of tasks is not exhaustive. Where You’ll Work - This is a France-based role - Travel within France, a priority country, is expected, as is travel to our international office in Zug, Switzerland, for team alignment and engagement. - Travel to other countries in the EU West region may also be required. Local team meetings and the designated office location in France are in the Paris area. ## Who You Are - 7–10 years of experience in HEOR, real-world evidence (RWE), or market access within industry, biotech, or specialized consulting - Direct, hands-on experience completing French market access dossiers, including submissions to the Transparency Committee, early access applications, and CEESP assessments - Strong knowledge of observational studies, medico-administrative databases, health economic modeling, and indirect comparisons - Proven experience managing vendors and budgets - Ability to influence without direct authority and collaborate with global, multidisciplinary teams - A background in pharmacy, medicine, epidemiology, health economics, or biostatistics, with a master’s or doctoral degree - Fluency in French and professional proficiency in English Strongly preferred - Experienced in rare or ultra-rare diseases - Experienced defending a surrogate endpoint or biomarker - Knowledge of French rare disease networks - Exposure to Belgian, Dutch, or Central and Eastern European systems - Initial people management experience - Experience in biotech or a fast-growing organization Expected attributes - Quickly operate independently, with a strong sense of ownership - Ability to prioritize across multiple geographies - Critical thinking and methodological rigor - Compelling communication in both French and English - Directness and clarity in all exchanges As a global company, our comprehensive benefits may vary based on location.  We have high expectations for our team members. We make sure those working hard for patients are rewarded and cared for in return. For BridgeBio Full-Time U.S Based Roles: Financial & Rewards - Market-leading compensation - 401(k) with employer match - Employee Stock Purchase Program (ESPP) - Pre-tax commuter benefits (transit and parking) - Referral bonus for hired candidates - Subsidized lunch and parking on in-office days Health & Well-Being - 100% employer-paid medical, dental, and vision premiums for you and your dependents - Health Savings Account (HSA) with annual employer contributions, plus Flexible Spending Accounts (FSA) - Fertility & family-forming benefits - Expanded mental health support (therapy and coaching resources) - Hybrid work model with flexibility - Flexible, “take-what-you-need” paid time off and company-paid holidays - Comprehensive paid medical and parental leave to care for yourself and your family Skill Development & Career Paths: - People are part of our growth and success story - from discovery to active drug trials and FDA pipelines, there are endless opportunities for skill development and internal mobility - We provide career pathing through regular feedback, continuous education and professional development programs via LinkedIn Learning, LifeLabs, & BetterUp Coaching - We celebrate strong performance with financial rewards, peer-to-peer recognition, and growth opportunities By applying, you acknowledge that BridgeBio will process your personal information as described in our [Global Candidate Privacy Notice](https://bridgebio.com/bridgebio-global-candidate-privacy-notice). Questions or requests: dataprivacy@bridgebio.com ## About BridgeBio Pharma ## Company Overview - **One-liner**: BridgeBio Pharma develops transformative medicines for genetic conditions, using a decentralized hub-and-spoke model to accelerate drug development from early research to commercialization. - **Entity Type**: Public (Nasdaq: BBIO) - **Headquarters**: Palo Alto, California, USA (with hybrid offices in San Francisco, CA) - **Founded**: Not explicitly stated in provided sources; the company references “over the past 10 years” as of 2026, suggesting founding around 2015–2016. - **Founders**: Not publicly available from provided sources. ## Core Business - **Primary industry**: Biotechnology / Genetic disease therapeutics - **Target customers**: Patients living with genetic conditions, healthcare providers, payers, and academic research partners - **Mission**: “To develop transformative medicines for genetic conditions” and “bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations.” ## Products & Services BridgeBio’s pipeline includes both approved therapies and investigational candidates across dozens of indications. Key offerings: - **Acoramidis**: Approved for transthyretin amyloidosis (ATTR) – a first-in-class treatment with $8B+ peak year sales potential. - **Infigratinib**: Phase 3 completed for achondroplasia; published in the *New England Journal of Medicine* (2026). - **BBP-418**: Investigational for Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9). - **Encaleret**: Investigational for Autosomal Dominant Hypocalcemia Type 1 (ADH1). - **BBP-812**: Investigational for Canavan Disease. - **BridgeBio Oncology Therapeutics (BBOT)**: Subsidiary focused on RAS and PI3Kα-driven cancers. - **GondolaBio**: Subsidiary developing bioavailable small molecule inhibitors for oncology. - **Other programs**: Covering hypochondroplasia, chronic hypoparathyroidism, and more. The company has received **3 FDA approvals** and has over **70+ peer-reviewed publications**. ## Market Standing - **Valuation / Market Cap**: Not explicitly stated in provided data; as a public company, current market cap can be found on financial platforms (e.g., ~$8B based on peak sales potential, but not a direct valuation number). - **Key Metric**: **3 FDA-approved medicines**; **2000+ patients enrolled** in global clinical trials; **6 Phase 3 trials** conducted over the past 10 years. - **Notable Investors / Partners**: Not detailed in provided sources, but the company partners with leading academic institutions to advance early-stage research. - **Growth Signals**: Recent publication of Phase 3 PROPEL 3 trial results in NEJM (June 2026); expansion into oncology via BBOT and GondolaBio; 100% of pipeline is first-in-class or best-in-class; 48 unique disease indications targeted. ## Competitive Advantages - **Hub-and-spoke model**: Decentralized structure where autonomous affiliate teams (spokes) focus on specific conditions, while a central hub provides clinical, regulatory, and commercial expertise. This enables speed, scalability, and risk reduction. - **First-in-class / best-in-class focus**: 100% of pipeline aims to be first or best in class, targeting underserved genetic conditions with clear biological rationale. - **Speed and adaptability**: The model allows rapid pivoting to the most promising opportunities, reducing development timelines compared to traditional biotech. - **Strong scientific foundation**: Over 70 peer-reviewed papers and collaborations with top academic institutions. ## Strategic Focus - **Advance late-stage pipeline**: Prioritize Phase 3 programs (e.g., infigratinib for achondroplasia, acoramidis for ATTR) and seek additional FDA approvals. - **Expand into oncology**: Leverage subsidiaries BBOT and GondolaBio to address RAS/PI3Kα-driven cancers. - **Maintain urgency**: “Every minute counts” – continue to operate with speed and autonomy to bring treatments to patients faster. - **Build on commercial success**: Leverage existing approved products to fund further R&D and expand global reach. ## Why Work Here - **Award-winning culture**: Named **#1 Best Place to Work** by BioSpace (2026, small biotech category) with an **88% employee engagement score** in 2025. - **Flexible work model**: Hybrid policy with offices in San Francisco and Palo Alto, CA; “flexible working model” emphasized. - **Compensation and benefits**: Market-leading pay, comprehensive healthcare, and strong emphasis on growth and internal mobility. - **Impact-driven mission**: Work on transformative treatments for genetic conditions where patient need is urgent – “Impatient for Patients” is a core mantra. - **Values**: Put patients first, let science speak, think independently, speak up, and act with urgency. The culture is described as “high on standards, low on convention.” - **Growth opportunities**: 113 open jobs (as of mid-2026) across functions including clinical, regulatory, manufacturing, commercial, and corporate; talent community available for future roles. ## Sources 1. [bridgebio.com](https://bridgebio.com/) – Home page with pipeline overview and $8B peak sales potential 2. [bridgebio.com/about](https://bridgebio.com/about) – Company description, hub-and-spoke model, and key metrics 3. [bridgebio.com/careers](https://bridgebio.com/careers) – Careers page with awards, culture, and benefits 4. [investor.bridgebio.com](https://investor.bridgebio.com/overview/default.aspx) – Investor relations overview, latest news, and corporate presentation 5. [job-boards.greenhouse.io/bridgebio](http://job-boards.greenhouse.io/bridgebio) – Current job listings (113 roles) and departmental categories ## Other roles at BridgeBio Pharma - [Executive Director/Vice President Global Media Relations, Executive Communications & Comm Ops](https://feeny.ai/job/executive-director-vice-president-global-media-relations-executive-8m4sdjpbpgt1) — Palo Alto - [Associate Director/ Director Customer Engagement, International](https://feeny.ai/job/associate-director-director-customer-engagement-international-bridgebio-pharma-r2e136fd40b5) — Zug, Switzerland - [Associate Director/ Director, Sales Force Effectiveness, International](https://feeny.ai/job/associate-director-director-sales-force-effectiveness-international-bridgebio-cbd6wfzs86ss) — Zug, Switzerland - [Senior Manager, Insights & Forecasting, International](https://feeny.ai/job/senior-manager-insights-forecasting-international-bridgebio-pharma-zug-11ax8v3ykxvd) — Zug, Switzerland - [Director, Managed Markets - Regional - West](https://feeny.ai/job/director-managed-markets-regional-west-bridgebio-pharma-united-states-apfnzdx6eqgf) — United States - [Director, Managed Markets - Regional - Central](https://feeny.ai/job/director-managed-markets-regional-central-bridgebio-pharma-united-states-dm447m7g3k3e) — United States - [Director, Managed Markets—National Accounts](https://feeny.ai/job/director-managed-markets-national-accounts-bridgebio-pharma-united-states-nf18z7wph0mz) — United States - [Senior Director, Market Access Strategy, International](https://feeny.ai/job/senior-director-market-access-strategy-international-bridgebio-pharma-zug-v4k5h0wh3b0c) — Zug, Switzerland - [Senior MLR Specialist](https://feeny.ai/job/senior-mlr-specialist-bridgebio-pharma-united-states-f1tbcn8vc88t) — United States - [Sr Director/Executive Director, Pharm Science Technical Lead](https://feeny.ai/job/sr-director-executive-director-pharm-science-technical-lead-bridgebio-pharma-x10e5rkhnna4) — San Francisco